Equillium, Inc.
2223 Avenida de la Playa
Suite 108
La Jollla
California
92037
United States
Tel: 858-864-3830
114 articles with Equillium, Inc.
-
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates
3/23/2023
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2022 and provided corporate and clinical development updates.
-
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
3/22/2023
Equillium, Inc. , today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference.
-
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
2/17/2023
Equillium, Inc. announced that an oral presentation was given yesterday afternoon at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.
-
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
2/7/2023
Equillium, Inc. today announced that it will present at the SVB Securities Annual Global Biopharma Conference.
-
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
1/13/2023
Equillium, Inc. today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.
-
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
12/23/2022
Equillium, Inc. and Metacrine, Inc. announced the mutual termination of their previously announced definitive merger agreement.
-
Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
12/23/2022
Metacrine, Inc. and Equillium, Inc. announced the mutual termination of their previously announced definitive merger agreement.
-
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
12/16/2022
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis (UC).
-
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
12/6/2022
Equillium grants Ono an option to purchase rights to itolizumab.
-
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
11/14/2022
Equillium, Inc. today announced that a poster presentation was given over the weekend at ACR Convergence, the annual meeting of the American College of Rheumatology.
-
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
11/14/2022
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2022 and provided an update on its clinical development programs.
-
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
11/10/2022
Equillium, Inc. today announced that it has initiated a Phase 2 open-label study of EQ101 to assess efficacy and safety in adult subjects with moderate to severe alopecia areata.
-
Equillium to Present at Two Upcoming November 2022 Investor Conferences
11/8/2022
Equillium, Inc. announced that it will participate in fireside chat presentations at the Stifel Healthcare Conference and the Jefferies London Healthcare Conference.
-
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
11/3/2022
Equillium, Inc. today announced a presentation at the 6th Annual Dermatology Drug Development Summit.
-
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease
11/2/2022
Equillium, Inc. today announced that it has initiated a Phase 1 study of EQ102 in healthy volunteers.
-
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
10/26/2022
Equillium, Inc. today announced data presented at the annual La Jolla Immunology Conference.
-
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
9/27/2022
Equillium, Inc. today announced interim results from the Type B portion of the EQUALISE study evaluating itolizumab, a first-in-class anti-CD6 monoclonal antibody selectively targeting the CD6-ALCAM pathway, in patients with lupus nephritis (LN).
-
Equillium, 9 Meters Biopharma and ABVC Biopharma have something to say about lupus, short bowel syndrome and ADHD.
-
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
9/15/2022
Equillium, Inc. today announced that an abstract was accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology.
-
Equillium to Acquire Metacrine in All-Stock Transaction
9/6/2022
Equillium, Inc. and Metacrine Inc., announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction.